Brief: Ngm Bio Initiates Expansion Of Ongoing Phase 1B Proof-Of-Concept Study Of Ngm120 In Patients With Metastatic Pancreatic Cancer
02/03/2021 13:05
March 2 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO INITIATES EXPANSION OF ONGOING PHASE 1B
PROOF-OF-CONCEPT
STUDY OF NGM120 IN PATIENTS WITH METASTATIC PANCREATIC CANCER
Source text for Eikon: ID:nGNXMvyts
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors